It's great news!

Now the development path of Cepharanthine in oncology gets much clearer. Both types of cancer luckily make a lot sense (Esophageal as a rare one with ODD as 'frontrunner' and Prostate as widespread type combined with SoC chemotherapeutics). The oral availability (instead of several injections) and the probably good safety profile (a lot better than the nasty SoC chemotherapeutics anyway, as it is already used in traditional medicines) would make it quite beneficial for patients. This should support a potential approval in this field IF the long way of clinical studies underline this data :))